GC Aesthetics PLC filed an amended F-1 form with the Securities and Exchange Commission (SEC) for its initial public offering (IPO). The expected price range for the offering was given as $13 to $15 for 5.35 million shares with an overallotment option of 802,500 shares. At the maximum price the total offering would be valued at roughly $92.29 million. The company intends to file on the NASDAQ Global Market under the symbol GCAA.

The underwriters for the offering are Merrill Lynch, Deutsche Bank, Cowen, and William Blair.

This is a leading pure-play female aesthetics company committed to becoming the trusted brand and partner for women seeking to look healthy, youthful, vibrant and beautiful, and to feel confident about themselves throughout their lifetime. Currently, the company focuses on the breast implant market outside of the United States, including pre- and post-breast implant surgery products globally.

The company has a presence in Europe, the Middle East and Africa (EMEA), Latin America and Asia-Pacific and it intends to continue to further expand in these regions, including China, Russia and the Middle East, and into new markets, including South Korea and Thailand for example.

Currently, GC Aesthetics is evaluating the clinical programs required to obtain regulatory approval for its implant products in North America. To date, it has generated significant growth by focusing on the development, manufacturing and commercialization of one of the broadest ranges of implant products, principally silicone breast implants. Beyond breast implant products, the company intends to expand its presence in other selected female aesthetics products, including those associated with implant surgery as well as other procedures, such as body sculpting treatments and dermal fillers.

What the company sees is an opportunity to capitalize on favorable trends in the aesthetics market and benefit from the underlying growth in women’s disposable income, particularly in emerging markets.

In the filing, GC Aesthetics detailed its finances as:

We have a diversified revenue base, with 47% of our 2014 revenues derived from sales in EMEA, 42% in Latin America and 11% in Asia-Pacific. Our revenues increased by 18% to $52.8 million for the year ended December 31, 2014, as compared to $44.6 million for the year ended December 31, 2013; foreign exchange fluctuations had no material impact on our revenue for this period. Our revenue increased by 20% to $13.0 million for the three months ended March 31, 2015, as compared to $10.8 million for the three months ended March 31, 2014; excluding the impact of changes in foreign exchange rates, we estimate that this represents growth of 31%.

The company intends to use the net proceeds of this offering to expand its sales and marketing activities in new and existing countries, its product portfolio and manufacturing capabilities. Additionally, GC Aesthetics intends to use the net proceeds of this offering to fund potential future acquisitions and for working capital, debt service and other general corporate purposes.

ALSO READ: 12 American Names Popular for the First Time

Thank you for reading! Have some feedback for us?
Contact the 24/7 Wall St. editorial team.